Historique
Rapport
Evolution of the U.S. overdose crisis. Understanding China's role in the production and supply of synthetic opioids
Auteur(s) :
PARDO, B.
Année
2018
Page(s) :
14 p.
Sous-type de document :
Témoignage / Testimony
Langue(s) :
Anglais
Éditeur(s) :
Santa Monica, CA : Rand Corporation
Domaine :
Autres substances / Other substances ; Drogues illicites / Illicit drugs
Discipline :
MAR (Marchés / Markets)
Thésaurus géographique
ETATS-UNIS
;
CHINE
Thésaurus mots-clés
OPIOIDES
;
DROGUES DE SYNTHESE
;
PRODUCTION
;
DIFFUSION DES PRODUITS
;
SURDOSE
;
FENTANYL
;
PRECURSEURS
;
REGULATION
;
POLITIQUE
Note générale :
Testimony presented before the House Foreign Affairs Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations on September 6, 2018
Résumé :
The introduction of illicitly manufactured synthetic opioids to U.S. drug markets presents new challenges for contemporary drug policy: The potency of many synthetic opioids increases risk to users and poses challenges for first responders, the development of novel opioids that fall outside existing drug controls complicates regulatory efforts, and their ability to be produced and shipped with ease disrupts traditional supply chains.
Today, I will briefly describe our country's ongoing opioid overdose crisis. Understanding recent developments and the shifting supply of opioids is critical to policy design. I will then describe the emergence of synthetic opioids, which have complicated many of our drug policy efforts. Given the topic of this hearing, I focus most of my testimony on China's role as a source of synthetic psychoactives and chemical precursors, describing what we know about the manufacture and export of potent opioids, such as fentanyl, to the United States. [Extract]
Today, I will briefly describe our country's ongoing opioid overdose crisis. Understanding recent developments and the shifting supply of opioids is critical to policy design. I will then describe the emergence of synthetic opioids, which have complicated many of our drug policy efforts. Given the topic of this hearing, I focus most of my testimony on China's role as a source of synthetic psychoactives and chemical precursors, describing what we know about the manufacture and export of potent opioids, such as fentanyl, to the United States. [Extract]
Affiliation :
The RAND Corporation, USA